person · Reporting owner

MCGUIRE TERRANCE

Disclosed activity across 11 companies

Tapewire entity: 27833
SEC CIK: 0001117003

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ACCELERON PHARMA INCXLRN · Entity 15780	Director	March 02, 2017	March 14, 2017
Alector, Inc.ALEC · Entity 6051	Director · 10% owner	September 11, 2023	September 13, 2023
Invivyd, Inc.IVVD · Entity 721	Director	May 19, 2026	May 21, 2026
Korsana Biosciences, Inc.CYCN · Entity 7698	Director	November 30, 2023	December 04, 2023
Lyra Therapeutics, Inc.LYRA · Entity 46837	10% owner	May 05, 2020	May 06, 2020
Pulmatrix, Inc.PULM · Entity 8249	Director	May 16, 2019	May 20, 2019
Seer, Inc.SEER · Entity 6717	Director	July 28, 2026	July 30, 2026
Tectonic Therapeutic, Inc.TECX · Entity 5328	Director	June 09, 2025	June 11, 2025
X4 Pharmaceuticals, IncASNS · Entity 5638	Director	June 05, 2018	June 07, 2018

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ACCELERON PHARMA INC

Report date March 02, 2017 · Filed March 14, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,250	Reported balance After 2017-03-02 transaction · row 1 1 source row Row 1 · 2017-03-02 · Grant · Acquired 1,250 · Balance 1,250
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $30.17 · Expires 2027-03-02	Direct	7,500	Reported balance After 2017-03-02 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2017-03-02 · Grant · Acquired 7,500 · Balance 7,500 F1: The shares of common stock underlying this stock option award vest in full on the one year anniversary of the grant date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares of common stock underlying this stock option award vest in full on the one year anniversary of the grant date.

Alector, Inc.

Report date September 11, 2023 · Filed September 13, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnote	10,853,817	Reported balance After 2023-09-11 transaction · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · 2023-09-11 · Sale · Disposed 500,000 · Balance 10,853,817 F1: 27,606 shares were sold by Polaris Venture Partners Founders' Fund VI, L.P. ("PVPFF VI"), 379,180 shares were sold by Polaris Venture Partners VI (AIV), L.P. ("PVP VI AIV") and 93,214 shares were sold by Polaris Venture Partners VI (AIV-B), L.P. (p/k/a PVP VI (AIV) Feeder Corp. Holding Partnership, L.P., "PVP VI AIV-B" and, together with PVPFF VI, PVP VI AIV and Polaris Venture Partners VI, L.P. ("PVP VI"), the "Polaris Funds"). F2: (Continued from footnote 1) The general partner of each of the Polaris Funds is Polaris Venture Management Co. VI, L.L.C. ("PVM"). Each of Amir Nashat, Brian Chee, David Barrett, Bryce Youngren, Jonathan Flint, and the Reporting Person, a member of the Issuer's board of directors, are managing members of PVM (collectively, the "Managing Members") and may be deemed to have shared power to vote and dispose of the shares held by the Polaris Funds. Each of the Managing Members and PVM disclaims beneficial ownership of the securities held by the Polaris Funds, and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interest therein. F3: 599,251 shares are held by PVPFF VI, 7,831,004 shares are held by PVP VI AIV, 1,925,094 shares are held by PVP VI AIV-B and 498,468 shares are held by PVP VI. Each of the Managing Members and PVM disclaims beneficial ownership of the securities held by the Polaris Funds, and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee footnote	39,399	Reported balance Holding disclosure · report date 2023-09-11 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 39,399 F5: Shares held by McGuire Family Trust. The Reporting Person, a member of the Issuer's board of directors, is the donor of McGuire Family Trust and may be deemed to have shared power to vote and dispose of the shares held by McGuire Family Trust.
Common StockSEC Table I · non-derivative	Direct	54,996	Reported balance Holding disclosure · report date 2023-09-11 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 54,996 F4: 26,250 of such shares are represented by restricted stock units, or RSUs, which vest on the earlier of (i) June 14, 2024 or (ii) the date of the Issuer's next annual meeting of stockholders.

Filing footnotes · ownership attribution and instrument terms

F1: 27,606 shares were sold by Polaris Venture Partners Founders' Fund VI, L.P. ("PVPFF VI"), 379,180 shares were sold by Polaris Venture Partners VI (AIV), L.P. ("PVP VI AIV") and 93,214 shares were sold by Polaris Venture Partners VI (AIV-B), L.P. (p/k/a PVP VI (AIV) Feeder Corp. Holding Partnership, L.P., "PVP VI AIV-B" and, together with PVPFF VI, PVP VI AIV and Polaris Venture Partners VI, L.P. ("PVP VI"), the "Polaris Funds").

F2: (Continued from footnote 1) The general partner of each of the Polaris Funds is Polaris Venture Management Co. VI, L.L.C. ("PVM"). Each of Amir Nashat, Brian Chee, David Barrett, Bryce Youngren, Jonathan Flint, and the Reporting Person, a member of the Issuer's board of directors, are managing members of PVM (collectively, the "Managing Members") and may be deemed to have shared power to vote and dispose of the shares held by the Polaris Funds. Each of the Managing Members and PVM disclaims beneficial ownership of the securities held by the Polaris Funds, and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interest therein.

F3: 599,251 shares are held by PVPFF VI, 7,831,004 shares are held by PVP VI AIV, 1,925,094 shares are held by PVP VI AIV-B and 498,468 shares are held by PVP VI. Each of the Managing Members and PVM disclaims beneficial ownership of the securities held by the Polaris Funds, and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interest therein.

F4: 26,250 of such shares are represented by restricted stock units, or RSUs, which vest on the earlier of (i) June 14, 2024 or (ii) the date of the Issuer's next annual meeting of stockholders.

F5: Shares held by McGuire Family Trust. The Reporting Person, a member of the Issuer's board of directors, is the donor of McGuire Family Trust and may be deemed to have shared power to vote and dispose of the shares held by McGuire Family Trust.

Invivyd, Inc.

Report date May 19, 2026 · Filed May 21, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.04 · Expires 2036-05-18	Direct	50,000	Reported balance After 2026-05-19 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-05-19 · Grant · Acquired 50,000 · Balance 50,000 F1: This option was granted on May 19, 2026 and vests in full upon the earlier of (i) May 19, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continuous service through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: This option was granted on May 19, 2026 and vests in full upon the earlier of (i) May 19, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continuous service through such vesting date.

Korsana Biosciences, Inc.

Report date November 30, 2023 · Filed December 04, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	5,552	Reported balance After 2023-11-30 transaction · row 1 1 source row Row 1 · 2023-11-30 · Grant · Acquired 5,000 · Balance 5,552 F1: The Reporting Person was granted 5,000 shares of restricted stock pursuant to the Cyclerion Therapeutics, Inc. 2019 Equity Incentive Plan. 2,500 of these shares vest immediately and the remaining 2,500 of these shares vest over the next 6 months, provided that the Reporting Person remains as a director of Cylerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions.
Common StockSEC Table I · non-derivative	IndirectBy Polaris Partners VIII, L.P	34,866	Reported balance Holding disclosure · report date 2023-11-30 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 34,866 F2: The reportable securities are owned directly by Polaris Partners VIII, L.P. ("PP VIII"). Polaris Partners GP VIII, L.L.C. ("PPGP VIII") is the general partner of PP VIII. The Reporting Person, a member of the Issuer's Board of Directors, is an interest holder of PPGP VIII. Each of David Barrett, Brian Chee, Amir Nashat and Bryce Youngren are the managing members of PPGP VIII (collectively, the "Managing Members"). Each of the Reporting Person and the Managing Members, in their respective capacities with respect to PPGP VIII, may be deemed to have shared voting and dispositive power over the shares held by PP VIII. Each of PPGP VIII, the Reporting Person and the Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Common StockSEC Table I · non-derivative	IndirectBy Polaris Entrepreneurs 'Fund VIII, L.P.	1,247	Reported balance Holding disclosure · report date 2023-11-30 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 1,247 F3: The reportable securities are owned directly by PEF VIII. PPGP VIII is the general partner of PEF VIII. The Reporting Person, a member of the Issuer's Board of Directors, is an interest holder of PPGPVIII. Each of the Reporting Person and the Managing Members, in their respective capacities with respect to PPGP VIII, may be deemed to have shared voting and dispositive power over the shares held by PEF VIII. Each of PPGP VIII, the Reporting Person and the Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Common StockSEC Table I · non-derivative	IndirectBy Bartlett Partners, LLC	345	Reported balance Holding disclosure · report date 2023-11-30 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 345 F4: The Reporting Person is a managing member of Bartlett Partners, LLC, the beneficial owner of the securities. The Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The Reporting Person was granted 5,000 shares of restricted stock pursuant to the Cyclerion Therapeutics, Inc. 2019 Equity Incentive Plan. 2,500 of these shares vest immediately and the remaining 2,500 of these shares vest over the next 6 months, provided that the Reporting Person remains as a director of Cylerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions.

F2: The reportable securities are owned directly by Polaris Partners VIII, L.P. ("PP VIII"). Polaris Partners GP VIII, L.L.C. ("PPGP VIII") is the general partner of PP VIII. The Reporting Person, a member of the Issuer's Board of Directors, is an interest holder of PPGP VIII. Each of David Barrett, Brian Chee, Amir Nashat and Bryce Youngren are the managing members of PPGP VIII (collectively, the "Managing Members"). Each of the Reporting Person and the Managing Members, in their respective capacities with respect to PPGP VIII, may be deemed to have shared voting and dispositive power over the shares held by PP VIII. Each of PPGP VIII, the Reporting Person and the Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

F3: The reportable securities are owned directly by PEF VIII. PPGP VIII is the general partner of PEF VIII. The Reporting Person, a member of the Issuer's Board of Directors, is an interest holder of PPGPVIII. Each of the Reporting Person and the Managing Members, in their respective capacities with respect to PPGP VIII, may be deemed to have shared voting and dispositive power over the shares held by PEF VIII. Each of PPGP VIII, the Reporting Person and the Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

F4: The Reporting Person is a managing member of Bartlett Partners, LLC, the beneficial owner of the securities. The Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.

Lyra Therapeutics, Inc.

Report date May 05, 2020 · Filed May 06, 2020

Jointly reported with Polaris Venture Management Co. V, L.L.C., Polaris Venture Partners Special Founders' Fund V, L.P., Polaris Venture Partners V, L.P., Polaris Venture Partners Entrepreneurs' Fund V, L.P., Polaris Venture Partners Founders' Fund V, L.P., Flint Jonathan A

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnote	993,981	Reported balance After 2020-05-05 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2020-05-05 · Conversion · Acquired 993,981 · Balance 993,981 F1: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F2: The reportable securities are owned directly by Polaris Venture Partners V, L.P. ("PVP V"). Polaris Venture Management Co. V, L.L.C. ("PVM V") is the general partner of PVP V. Each of Jonathan A. Flint ("Flint") and Terrance G. McGuire ("McGuire") are the managing members of PVM V and may be deemed to have shared voting and dispositive power over the shares held by PVP V. Each of PVM V, Flint and McGuire disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Common StockSEC Table I · non-derivative	IndirectSee footnote	19,370	Reported balance After 2020-05-05 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2020-05-05 · Conversion · Acquired 19,370 · Balance 19,370 F1: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F3: The reportable securities are owned directly by Polaris Venture Partners Entrepreneurs' Fund V, L.P. ("PVPE V"). PVM V is the general partner of PVPE V. Each of Flint and McGuire are the managing members of PVM V and may be deemed to have shared voting and dispositive power over the shares held by PVPE V. Each of PVM V, Flint and McGuire disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Common StockSEC Table I · non-derivative	IndirectSee footnote	9,936	Reported balance After 2020-05-05 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2020-05-05 · Conversion · Acquired 9,936 · Balance 9,936 F1: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F4: The reportable securities are owned directly by Polaris Venture Partners Special Founders' Fund V, L.P. ("PVPSFF V"). PVM V is the general partner of PVPSFF V. Each of Flint and McGuire are the managing members of PVM V and may be deemed to have shared voting and dispositive power over the shares held by PVPSFF V. Each of PVM V, Flint and McGuire disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Common StockSEC Table I · non-derivative	IndirectSee footnote	6,807	Reported balance After 2020-05-05 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 4 · 2020-05-05 · Conversion · Acquired 6,807 · Balance 6,807 F1: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F5: The reportable securities are owned directly by Polaris Venture Partners Founders' Fund V, L.P. ("PVPFF V"). PVM V is the general partner of PVPFF V. Each of Flint and McGuire are the managing members of PVM V and may be deemed to have shared voting and dispositive power over the shares held by PVPFF V. Each of PVM V, Flint and McGuire disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Common StockSEC Table I · non-derivative	IndirectSee footnote	1,011,285	Reported balance After 2020-05-05 transaction · row 5 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 5 · 2020-05-05 · Other · Acquired 17,304 · Balance 1,011,285 F2: The reportable securities are owned directly by Polaris Venture Partners V, L.P. ("PVP V"). Polaris Venture Management Co. V, L.L.C. ("PVM V") is the general partner of PVP V. Each of Jonathan A. Flint ("Flint") and Terrance G. McGuire ("McGuire") are the managing members of PVM V and may be deemed to have shared voting and dispositive power over the shares held by PVP V. Each of PVM V, Flint and McGuire disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Common StockSEC Table I · non-derivative	IndirectSee footnote	1,001,951	Reported balance After 2020-05-05 transaction · row 6 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 6 · 2020-05-05 · Sale · Disposed 9,334 · Balance 1,001,951 F6: On May 5, 2020, PVP V exercised a warrant to purchase 17,304 shares of the Issuer's common stock for $16.00 a share, which represents the Issuer's initial public offering price. In connection with the automatic net exercise of the warrant immediately prior to the closing of the Issuer's initial public offering, the Issuer withheld 9,334 of the warrant shares to pay the exercise price and issued the remaining warrant shares to PVP V. The Issuer also paid $10.48 to PVP V in lieu of a fractional share. F2: The reportable securities are owned directly by Polaris Venture Partners V, L.P. ("PVP V"). Polaris Venture Management Co. V, L.L.C. ("PVM V") is the general partner of PVP V. Each of Jonathan A. Flint ("Flint") and Terrance G. McGuire ("McGuire") are the managing members of PVM V and may be deemed to have shared voting and dispositive power over the shares held by PVP V. Each of PVM V, Flint and McGuire disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Common StockSEC Table I · non-derivative	IndirectSee footnote	19,707	Reported balance After 2020-05-05 transaction · row 7 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 7 · 2020-05-05 · Other · Acquired 337 · Balance 19,707 F3: The reportable securities are owned directly by Polaris Venture Partners Entrepreneurs' Fund V, L.P. ("PVPE V"). PVM V is the general partner of PVPE V. Each of Flint and McGuire are the managing members of PVM V and may be deemed to have shared voting and dispositive power over the shares held by PVPE V. Each of PVM V, Flint and McGuire disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Common StockSEC Table I · non-derivative	IndirectSee footnote	19,525	Reported balance After 2020-05-05 transaction · row 8 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 8 · 2020-05-05 · Sale · Disposed 182 · Balance 19,525 F7: On May 5, 2020, PVPE V exercised a warrant to purchsae 337 shares of the Issuer's common stock for $16.00 a share, which represents the Issuer's initial public offering price. In connection with the automatic net exercise of the warrant immediately prior to the closing of the Issuer's initial public offering, the Issuer withheld 182 of the warrant shares to pay the exercise price and issued the remaining warrant shares to PVPE V. The Issuer also paid $3.69 to PVPE V in lieu of a fractional share. F3: The reportable securities are owned directly by Polaris Venture Partners Entrepreneurs' Fund V, L.P. ("PVPE V"). PVM V is the general partner of PVPE V. Each of Flint and McGuire are the managing members of PVM V and may be deemed to have shared voting and dispositive power over the shares held by PVPE V. Each of PVM V, Flint and McGuire disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Common StockSEC Table I · non-derivative	IndirectSee footnote	10,109	Reported balance After 2020-05-05 transaction · row 9 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 9 · 2020-05-05 · Other · Acquired 173 · Balance 10,109 F4: The reportable securities are owned directly by Polaris Venture Partners Special Founders' Fund V, L.P. ("PVPSFF V"). PVM V is the general partner of PVPSFF V. Each of Flint and McGuire are the managing members of PVM V and may be deemed to have shared voting and dispositive power over the shares held by PVPSFF V. Each of PVM V, Flint and McGuire disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Common StockSEC Table I · non-derivative	IndirectSee footnote	10,015	Reported balance After 2020-05-05 transaction · row 10 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 10 · 2020-05-05 · Sale · Disposed 94 · Balance 10,015 F8: On May 5, 2020, PVPSFF V exercised a warrant to purchase 173 shares of the Issuer's common stock for $16.00 a share, which represents the Issuer's initial public offering price. In connection with the automatic net exercise of the warrant immediately prior to the closing of the Issuer's initial public offering, the Issuer withheld 94 of the warrant shares to pay the exercise price and issued the remaining warrant shares to PVPSFF V. The Issuer also paid $11.01 to PVPSFF V in lieu of a fractional share. F4: The reportable securities are owned directly by Polaris Venture Partners Special Founders' Fund V, L.P. ("PVPSFF V"). PVM V is the general partner of PVPSFF V. Each of Flint and McGuire are the managing members of PVM V and may be deemed to have shared voting and dispositive power over the shares held by PVPSFF V. Each of PVM V, Flint and McGuire disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Common StockSEC Table I · non-derivative	IndirectSee footnote	6,925	Reported balance After 2020-05-05 transaction · row 11 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 11 · 2020-05-05 · Other · Acquired 118 · Balance 6,925 F5: The reportable securities are owned directly by Polaris Venture Partners Founders' Fund V, L.P. ("PVPFF V"). PVM V is the general partner of PVPFF V. Each of Flint and McGuire are the managing members of PVM V and may be deemed to have shared voting and dispositive power over the shares held by PVPFF V. Each of PVM V, Flint and McGuire disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Common StockSEC Table I · non-derivative	IndirectSee footnote	6,861	Reported balance After 2020-05-05 transaction · row 12 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 12 · 2020-05-05 · Sale · Disposed 64 · Balance 6,861 F9: On May 5, 2020, PVPFF V exercised a warrant to purchase 118 shares of the Issuer's common stock for $16.00 a share, which represents the Issuer's initial public offering price. In connection with the automatic net exercise of the warrant immediately prior to the closing of the Issuer's initial public offering, the Issuer withheld 64 of the warrant shares to pay the exercise price and issued the remaining warrant shares to PVPFF V. The Issuer also paid $5.66 to the PVPFF V in lieu of a fractional share. F5: The reportable securities are owned directly by Polaris Venture Partners Founders' Fund V, L.P. ("PVPFF V"). PVM V is the general partner of PVPFF V. Each of Flint and McGuire are the managing members of PVM V and may be deemed to have shared voting and dispositive power over the shares held by PVPFF V. Each of PVM V, Flint and McGuire disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Common StockSEC Table I · non-derivative	IndirectSee footnote	1,062,259	Reported balance After 2020-05-05 transaction · row 13 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 13 · 2020-05-05 · Purchase · Acquired 60,308 · Balance 1,062,259 F2: The reportable securities are owned directly by Polaris Venture Partners V, L.P. ("PVP V"). Polaris Venture Management Co. V, L.L.C. ("PVM V") is the general partner of PVP V. Each of Jonathan A. Flint ("Flint") and Terrance G. McGuire ("McGuire") are the managing members of PVM V and may be deemed to have shared voting and dispositive power over the shares held by PVP V. Each of PVM V, Flint and McGuire disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Common StockSEC Table I · non-derivative	IndirectSee footnote	20,701	Reported balance After 2020-05-05 transaction · row 14 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 14 · 2020-05-05 · Purchase · Acquired 1,176 · Balance 20,701 F3: The reportable securities are owned directly by Polaris Venture Partners Entrepreneurs' Fund V, L.P. ("PVPE V"). PVM V is the general partner of PVPE V. Each of Flint and McGuire are the managing members of PVM V and may be deemed to have shared voting and dispositive power over the shares held by PVPE V. Each of PVM V, Flint and McGuire disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Common StockSEC Table I · non-derivative	IndirectSee footnote	10,618	Reported balance After 2020-05-05 transaction · row 15 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 15 · 2020-05-05 · Purchase · Acquired 603 · Balance 10,618 F4: The reportable securities are owned directly by Polaris Venture Partners Special Founders' Fund V, L.P. ("PVPSFF V"). PVM V is the general partner of PVPSFF V. Each of Flint and McGuire are the managing members of PVM V and may be deemed to have shared voting and dispositive power over the shares held by PVPSFF V. Each of PVM V, Flint and McGuire disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Common StockSEC Table I · non-derivative	IndirectSee footnote	7,274	Reported balance After 2020-05-05 transaction · row 16 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 16 · 2020-05-05 · Purchase · Acquired 413 · Balance 7,274 F5: The reportable securities are owned directly by Polaris Venture Partners Founders' Fund V, L.P. ("PVPFF V"). PVM V is the general partner of PVPFF V. Each of Flint and McGuire are the managing members of PVM V and may be deemed to have shared voting and dispositive power over the shares held by PVPFF V. Each of PVM V, Flint and McGuire disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Series A-1/C Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-05-05 transaction · row 17 Instrument identity requires review; Table II rows are not merged. 1 source row Row 17 · 2020-05-05 · Conversion · Disposed 6,268,687 · Balance 0 F1: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F2: The reportable securities are owned directly by Polaris Venture Partners V, L.P. ("PVP V"). Polaris Venture Management Co. V, L.L.C. ("PVM V") is the general partner of PVP V. Each of Jonathan A. Flint ("Flint") and Terrance G. McGuire ("McGuire") are the managing members of PVM V and may be deemed to have shared voting and dispositive power over the shares held by PVP V. Each of PVM V, Flint and McGuire disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Series A-1/C Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-05-05 transaction · row 18 Instrument identity requires review; Table II rows are not merged. 1 source row Row 18 · 2020-05-05 · Conversion · Disposed 122,177 · Balance 0 F1: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F3: The reportable securities are owned directly by Polaris Venture Partners Entrepreneurs' Fund V, L.P. ("PVPE V"). PVM V is the general partner of PVPE V. Each of Flint and McGuire are the managing members of PVM V and may be deemed to have shared voting and dispositive power over the shares held by PVPE V. Each of PVM V, Flint and McGuire disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Series A-1/C Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-05-05 transaction · row 19 Instrument identity requires review; Table II rows are not merged. 1 source row Row 19 · 2020-05-05 · Conversion · Disposed 62,687 · Balance 0 F1: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F4: The reportable securities are owned directly by Polaris Venture Partners Special Founders' Fund V, L.P. ("PVPSFF V"). PVM V is the general partner of PVPSFF V. Each of Flint and McGuire are the managing members of PVM V and may be deemed to have shared voting and dispositive power over the shares held by PVPSFF V. Each of PVM V, Flint and McGuire disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Series A-1/C Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-05-05 transaction · row 20 Instrument identity requires review; Table II rows are not merged. 1 source row Row 20 · 2020-05-05 · Conversion · Disposed 42,941 · Balance 0 F1: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F5: The reportable securities are owned directly by Polaris Venture Partners Founders' Fund V, L.P. ("PVPFF V"). PVM V is the general partner of PVPFF V. Each of Flint and McGuire are the managing members of PVM V and may be deemed to have shared voting and dispositive power over the shares held by PVPFF V. Each of PVM V, Flint and McGuire disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Series A-2 Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-05-05 transaction · row 21 Instrument identity requires review; Table II rows are not merged. 1 source row Row 21 · 2020-05-05 · Conversion · Disposed 3,296,014 · Balance 0 F1: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F2: The reportable securities are owned directly by Polaris Venture Partners V, L.P. ("PVP V"). Polaris Venture Management Co. V, L.L.C. ("PVM V") is the general partner of PVP V. Each of Jonathan A. Flint ("Flint") and Terrance G. McGuire ("McGuire") are the managing members of PVM V and may be deemed to have shared voting and dispositive power over the shares held by PVP V. Each of PVM V, Flint and McGuire disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Series A-2 Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-05-05 transaction · row 22 Instrument identity requires review; Table II rows are not merged. 1 source row Row 22 · 2020-05-05 · Conversion · Disposed 64,237 · Balance 0 F1: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F3: The reportable securities are owned directly by Polaris Venture Partners Entrepreneurs' Fund V, L.P. ("PVPE V"). PVM V is the general partner of PVPE V. Each of Flint and McGuire are the managing members of PVM V and may be deemed to have shared voting and dispositive power over the shares held by PVPE V. Each of PVM V, Flint and McGuire disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Series A-2 Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-05-05 transaction · row 23 Instrument identity requires review; Table II rows are not merged. 1 source row Row 23 · 2020-05-05 · Conversion · Disposed 32,961 · Balance 0 F1: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F4: The reportable securities are owned directly by Polaris Venture Partners Special Founders' Fund V, L.P. ("PVPSFF V"). PVM V is the general partner of PVPSFF V. Each of Flint and McGuire are the managing members of PVM V and may be deemed to have shared voting and dispositive power over the shares held by PVPSFF V. Each of PVM V, Flint and McGuire disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Series A-2 Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-05-05 transaction · row 24 Instrument identity requires review; Table II rows are not merged. 1 source row Row 24 · 2020-05-05 · Conversion · Disposed 22,580 · Balance 0 F1: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F5: The reportable securities are owned directly by Polaris Venture Partners Founders' Fund V, L.P. ("PVPFF V"). PVM V is the general partner of PVPFF V. Each of Flint and McGuire are the managing members of PVM V and may be deemed to have shared voting and dispositive power over the shares held by PVPFF V. Each of PVM V, Flint and McGuire disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Series A-3 Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-05-05 transaction · row 25 Instrument identity requires review; Table II rows are not merged. 1 source row Row 25 · 2020-05-05 · Conversion · Disposed 8,610,081 · Balance 0 F1: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F2: The reportable securities are owned directly by Polaris Venture Partners V, L.P. ("PVP V"). Polaris Venture Management Co. V, L.L.C. ("PVM V") is the general partner of PVP V. Each of Jonathan A. Flint ("Flint") and Terrance G. McGuire ("McGuire") are the managing members of PVM V and may be deemed to have shared voting and dispositive power over the shares held by PVP V. Each of PVM V, Flint and McGuire disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Series A-3 Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-05-05 transaction · row 26 Instrument identity requires review; Table II rows are not merged. 1 source row Row 26 · 2020-05-05 · Conversion · Disposed 167,809 · Balance 0 F1: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F3: The reportable securities are owned directly by Polaris Venture Partners Entrepreneurs' Fund V, L.P. ("PVPE V"). PVM V is the general partner of PVPE V. Each of Flint and McGuire are the managing members of PVM V and may be deemed to have shared voting and dispositive power over the shares held by PVPE V. Each of PVM V, Flint and McGuire disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Series A-3 Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-05-05 transaction · row 27 Instrument identity requires review; Table II rows are not merged. 1 source row Row 27 · 2020-05-05 · Conversion · Disposed 86,101 · Balance 0 F1: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F4: The reportable securities are owned directly by Polaris Venture Partners Special Founders' Fund V, L.P. ("PVPSFF V"). PVM V is the general partner of PVPSFF V. Each of Flint and McGuire are the managing members of PVM V and may be deemed to have shared voting and dispositive power over the shares held by PVPSFF V. Each of PVM V, Flint and McGuire disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Series A-3 Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-05-05 transaction · row 28 Instrument identity requires review; Table II rows are not merged. 1 source row Row 28 · 2020-05-05 · Conversion · Disposed 58,980 · Balance 0 F1: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F5: The reportable securities are owned directly by Polaris Venture Partners Founders' Fund V, L.P. ("PVPFF V"). PVM V is the general partner of PVPFF V. Each of Flint and McGuire are the managing members of PVM V and may be deemed to have shared voting and dispositive power over the shares held by PVPFF V. Each of PVM V, Flint and McGuire disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Series A-4 Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-05-05 transaction · row 29 Instrument identity requires review; Table II rows are not merged. 1 source row Row 29 · 2020-05-05 · Conversion · Disposed 7,693,406 · Balance 0 F1: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F2: The reportable securities are owned directly by Polaris Venture Partners V, L.P. ("PVP V"). Polaris Venture Management Co. V, L.L.C. ("PVM V") is the general partner of PVP V. Each of Jonathan A. Flint ("Flint") and Terrance G. McGuire ("McGuire") are the managing members of PVM V and may be deemed to have shared voting and dispositive power over the shares held by PVP V. Each of PVM V, Flint and McGuire disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Series A-4 Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-05-05 transaction · row 30 Instrument identity requires review; Table II rows are not merged. 1 source row Row 30 · 2020-05-05 · Conversion · Disposed 149,944 · Balance 0 F1: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F3: The reportable securities are owned directly by Polaris Venture Partners Entrepreneurs' Fund V, L.P. ("PVPE V"). PVM V is the general partner of PVPE V. Each of Flint and McGuire are the managing members of PVM V and may be deemed to have shared voting and dispositive power over the shares held by PVPE V. Each of PVM V, Flint and McGuire disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Series A-4 Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-05-05 transaction · row 31 Instrument identity requires review; Table II rows are not merged. 1 source row Row 31 · 2020-05-05 · Conversion · Disposed 76,934 · Balance 0 F1: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F4: The reportable securities are owned directly by Polaris Venture Partners Special Founders' Fund V, L.P. ("PVPSFF V"). PVM V is the general partner of PVPSFF V. Each of Flint and McGuire are the managing members of PVM V and may be deemed to have shared voting and dispositive power over the shares held by PVPSFF V. Each of PVM V, Flint and McGuire disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Series A-4 Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-05-05 transaction · row 32 Instrument identity requires review; Table II rows are not merged. 1 source row Row 32 · 2020-05-05 · Conversion · Disposed 52,700 · Balance 0 F1: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F5: The reportable securities are owned directly by Polaris Venture Partners Founders' Fund V, L.P. ("PVPFF V"). PVM V is the general partner of PVPFF V. Each of Flint and McGuire are the managing members of PVM V and may be deemed to have shared voting and dispositive power over the shares held by PVPFF V. Each of PVM V, Flint and McGuire disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Series B Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-05-05 transaction · row 33 Instrument identity requires review; Table II rows are not merged. 1 source row Row 33 · 2020-05-05 · Conversion · Disposed 6,418,387 · Balance 0 F1: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F2: The reportable securities are owned directly by Polaris Venture Partners V, L.P. ("PVP V"). Polaris Venture Management Co. V, L.L.C. ("PVM V") is the general partner of PVP V. Each of Jonathan A. Flint ("Flint") and Terrance G. McGuire ("McGuire") are the managing members of PVM V and may be deemed to have shared voting and dispositive power over the shares held by PVP V. Each of PVM V, Flint and McGuire disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Series B Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-05-05 transaction · row 34 Instrument identity requires review; Table II rows are not merged. 1 source row Row 34 · 2020-05-05 · Conversion · Disposed 125,094 · Balance 0 F1: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F3: The reportable securities are owned directly by Polaris Venture Partners Entrepreneurs' Fund V, L.P. ("PVPE V"). PVM V is the general partner of PVPE V. Each of Flint and McGuire are the managing members of PVM V and may be deemed to have shared voting and dispositive power over the shares held by PVPE V. Each of PVM V, Flint and McGuire disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Series B Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-05-05 transaction · row 35 Instrument identity requires review; Table II rows are not merged. 1 source row Row 35 · 2020-05-05 · Conversion · Disposed 64,183 · Balance 0 F1: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F4: The reportable securities are owned directly by Polaris Venture Partners Special Founders' Fund V, L.P. ("PVPSFF V"). PVM V is the general partner of PVPSFF V. Each of Flint and McGuire are the managing members of PVM V and may be deemed to have shared voting and dispositive power over the shares held by PVPSFF V. Each of PVM V, Flint and McGuire disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Series B Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-05-05 transaction · row 36 Instrument identity requires review; Table II rows are not merged. 1 source row Row 36 · 2020-05-05 · Conversion · Disposed 43,966 · Balance 0 F1: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F5: The reportable securities are owned directly by Polaris Venture Partners Founders' Fund V, L.P. ("PVPFF V"). PVM V is the general partner of PVPFF V. Each of Flint and McGuire are the managing members of PVM V and may be deemed to have shared voting and dispositive power over the shares held by PVPFF V. Each of PVM V, Flint and McGuire disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Series C Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-05-05 transaction · row 37 Instrument identity requires review; Table II rows are not merged. 1 source row Row 37 · 2020-05-05 · Conversion · Disposed 1,988,991 · Balance 0 F1: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F2: The reportable securities are owned directly by Polaris Venture Partners V, L.P. ("PVP V"). Polaris Venture Management Co. V, L.L.C. ("PVM V") is the general partner of PVP V. Each of Jonathan A. Flint ("Flint") and Terrance G. McGuire ("McGuire") are the managing members of PVM V and may be deemed to have shared voting and dispositive power over the shares held by PVP V. Each of PVM V, Flint and McGuire disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Series C Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-05-05 transaction · row 38 Instrument identity requires review; Table II rows are not merged. 1 source row Row 38 · 2020-05-05 · Conversion · Disposed 38,765 · Balance 0 F1: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F3: The reportable securities are owned directly by Polaris Venture Partners Entrepreneurs' Fund V, L.P. ("PVPE V"). PVM V is the general partner of PVPE V. Each of Flint and McGuire are the managing members of PVM V and may be deemed to have shared voting and dispositive power over the shares held by PVPE V. Each of PVM V, Flint and McGuire disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Series C Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-05-05 transaction · row 39 Instrument identity requires review; Table II rows are not merged. 1 source row Row 39 · 2020-05-05 · Conversion · Disposed 19,890 · Balance 0 F1: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F4: The reportable securities are owned directly by Polaris Venture Partners Special Founders' Fund V, L.P. ("PVPSFF V"). PVM V is the general partner of PVPSFF V. Each of Flint and McGuire are the managing members of PVM V and may be deemed to have shared voting and dispositive power over the shares held by PVPSFF V. Each of PVM V, Flint and McGuire disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Series C Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-05-05 transaction · row 40 Instrument identity requires review; Table II rows are not merged. 1 source row Row 40 · 2020-05-05 · Conversion · Disposed 13,625 · Balance 0 F1: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F5: The reportable securities are owned directly by Polaris Venture Partners Founders' Fund V, L.P. ("PVPFF V"). PVM V is the general partner of PVPFF V. Each of Flint and McGuire are the managing members of PVM V and may be deemed to have shared voting and dispositive power over the shares held by PVPFF V. Each of PVM V, Flint and McGuire disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Common WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $8.63 · Expires 2030-01-10	IndirectSee footnote	0	Reported balance After 2020-05-05 transaction · row 41 Instrument identity requires review; Table II rows are not merged. 1 source row Row 41 · 2020-05-05 · Other · Disposed 17,304 · Balance 0 F1: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F2: The reportable securities are owned directly by Polaris Venture Partners V, L.P. ("PVP V"). Polaris Venture Management Co. V, L.L.C. ("PVM V") is the general partner of PVP V. Each of Jonathan A. Flint ("Flint") and Terrance G. McGuire ("McGuire") are the managing members of PVM V and may be deemed to have shared voting and dispositive power over the shares held by PVP V. Each of PVM V, Flint and McGuire disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Common WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $8.63 · Expires 2030-01-10	IndirectSee footnote	0	Reported balance After 2020-05-05 transaction · row 42 Instrument identity requires review; Table II rows are not merged. 1 source row Row 42 · 2020-05-05 · Other · Disposed 337 · Balance 0 F1: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F3: The reportable securities are owned directly by Polaris Venture Partners Entrepreneurs' Fund V, L.P. ("PVPE V"). PVM V is the general partner of PVPE V. Each of Flint and McGuire are the managing members of PVM V and may be deemed to have shared voting and dispositive power over the shares held by PVPE V. Each of PVM V, Flint and McGuire disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Common WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $8.63 · Expires 2030-01-10	IndirectSee footnote	0	Reported balance After 2020-05-05 transaction · row 43 Instrument identity requires review; Table II rows are not merged. 1 source row Row 43 · 2020-05-05 · Other · Disposed 173 · Balance 0 F1: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F4: The reportable securities are owned directly by Polaris Venture Partners Special Founders' Fund V, L.P. ("PVPSFF V"). PVM V is the general partner of PVPSFF V. Each of Flint and McGuire are the managing members of PVM V and may be deemed to have shared voting and dispositive power over the shares held by PVPSFF V. Each of PVM V, Flint and McGuire disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Common WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $8.63 · Expires 2030-01-10	IndirectSee footnote	0	Reported balance After 2020-05-05 transaction · row 44 Instrument identity requires review; Table II rows are not merged. 1 source row Row 44 · 2020-05-05 · Other · Disposed 118 · Balance 0 F1: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F5: The reportable securities are owned directly by Polaris Venture Partners Founders' Fund V, L.P. ("PVPFF V"). PVM V is the general partner of PVPFF V. Each of Flint and McGuire are the managing members of PVM V and may be deemed to have shared voting and dispositive power over the shares held by PVPFF V. Each of PVM V, Flint and McGuire disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date.

F2: The reportable securities are owned directly by Polaris Venture Partners V, L.P. ("PVP V"). Polaris Venture Management Co. V, L.L.C. ("PVM V") is the general partner of PVP V. Each of Jonathan A. Flint ("Flint") and Terrance G. McGuire ("McGuire") are the managing members of PVM V and may be deemed to have shared voting and dispositive power over the shares held by PVP V. Each of PVM V, Flint and McGuire disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

F3: The reportable securities are owned directly by Polaris Venture Partners Entrepreneurs' Fund V, L.P. ("PVPE V"). PVM V is the general partner of PVPE V. Each of Flint and McGuire are the managing members of PVM V and may be deemed to have shared voting and dispositive power over the shares held by PVPE V. Each of PVM V, Flint and McGuire disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

F4: The reportable securities are owned directly by Polaris Venture Partners Special Founders' Fund V, L.P. ("PVPSFF V"). PVM V is the general partner of PVPSFF V. Each of Flint and McGuire are the managing members of PVM V and may be deemed to have shared voting and dispositive power over the shares held by PVPSFF V. Each of PVM V, Flint and McGuire disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

F5: The reportable securities are owned directly by Polaris Venture Partners Founders' Fund V, L.P. ("PVPFF V"). PVM V is the general partner of PVPFF V. Each of Flint and McGuire are the managing members of PVM V and may be deemed to have shared voting and dispositive power over the shares held by PVPFF V. Each of PVM V, Flint and McGuire disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

F6: On May 5, 2020, PVP V exercised a warrant to purchase 17,304 shares of the Issuer's common stock for $16.00 a share, which represents the Issuer's initial public offering price. In connection with the automatic net exercise of the warrant immediately prior to the closing of the Issuer's initial public offering, the Issuer withheld 9,334 of the warrant shares to pay the exercise price and issued the remaining warrant shares to PVP V. The Issuer also paid $10.48 to PVP V in lieu of a fractional share.

F7: On May 5, 2020, PVPE V exercised a warrant to purchsae 337 shares of the Issuer's common stock for $16.00 a share, which represents the Issuer's initial public offering price. In connection with the automatic net exercise of the warrant immediately prior to the closing of the Issuer's initial public offering, the Issuer withheld 182 of the warrant shares to pay the exercise price and issued the remaining warrant shares to PVPE V. The Issuer also paid $3.69 to PVPE V in lieu of a fractional share.

F8: On May 5, 2020, PVPSFF V exercised a warrant to purchase 173 shares of the Issuer's common stock for $16.00 a share, which represents the Issuer's initial public offering price. In connection with the automatic net exercise of the warrant immediately prior to the closing of the Issuer's initial public offering, the Issuer withheld 94 of the warrant shares to pay the exercise price and issued the remaining warrant shares to PVPSFF V. The Issuer also paid $11.01 to PVPSFF V in lieu of a fractional share.

F9: On May 5, 2020, PVPFF V exercised a warrant to purchase 118 shares of the Issuer's common stock for $16.00 a share, which represents the Issuer's initial public offering price. In connection with the automatic net exercise of the warrant immediately prior to the closing of the Issuer's initial public offering, the Issuer withheld 64 of the warrant shares to pay the exercise price and issued the remaining warrant shares to PVPFF V. The Issuer also paid $5.66 to the PVPFF V in lieu of a fractional share.

Pulmatrix, Inc.

Report date May 16, 2019 · Filed May 20, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.06 · Expires 2029-05-16	Direct	15,000	Reported balance After 2019-05-16 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2019-05-16 · Grant · Acquired 15,000 · Balance 15,000 F1: The option vests in forty-eight (48) equal monthly installments on the 16th day of each month, with the first tranche vesting on June 16, 2019, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests in forty-eight (48) equal monthly installments on the 16th day of each month, with the first tranche vesting on June 16, 2019, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan.

Seer, Inc.

Report date July 28, 2026 · Filed July 30, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	128,566	Reported balance After 2026-07-28 transaction · row 1 1 source row Row 1 · 2026-07-28 · Grant · Acquired 16,500 · Balance 128,566 F1: The reported shares are represented by restricted stock units, or RSUs, which vest on the earlier of (i) July 28, 2027 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.14 · Expires 2036-07-28	Direct	25,000	Reported balance After 2026-07-28 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-07-28 · Grant · Acquired 25,000 · Balance 25,000 F4: Shares subject to the option vest on the earlier of (i) July 28, 2027 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders.
Class A Common StockSEC Table I · non-derivative	IndirectSee footnote	215,070	Reported balance Holding disclosure · report date 2026-07-28 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 215,070 F2: The reported shares are held of record by Strong Bridge, LLC for which the Reporting Person serves as an operating manager.
Class A Common StockSEC Table I · non-derivative	IndirectSee footnote	78,947	Reported balance Holding disclosure · report date 2026-07-28 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 78,947 F3: The reported shares are held of record by Polaris Founders Capital Fund I, L.P. ("PFCF I"). Polaris Founders Capital Management Co. I, L.L.C. ("PFCM"), is the general partner of PFCF I. The Reporting Person and Jonathan A. Flint ("Flint") are the managing members of PFCM. Each of the Reporting Person and Flint in their respective capacities with respect to PFCM may be deemed to have shared voting and dispositive power with respect to the shares held by PFCF I. Each of PFCM, Flint, and the Reporting Person disclaims beneficial ownership of securities held by PFCF I, and this report shall not be deemed an admission that the Reporting Person, Flint, or PFCM is the beneficial owner of these securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Filing footnotes · ownership attribution and instrument terms

F1: The reported shares are represented by restricted stock units, or RSUs, which vest on the earlier of (i) July 28, 2027 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders.

F2: The reported shares are held of record by Strong Bridge, LLC for which the Reporting Person serves as an operating manager.

F3: The reported shares are held of record by Polaris Founders Capital Fund I, L.P. ("PFCF I"). Polaris Founders Capital Management Co. I, L.L.C. ("PFCM"), is the general partner of PFCF I. The Reporting Person and Jonathan A. Flint ("Flint") are the managing members of PFCM. Each of the Reporting Person and Flint in their respective capacities with respect to PFCM may be deemed to have shared voting and dispositive power with respect to the shares held by PFCF I. Each of PFCM, Flint, and the Reporting Person disclaims beneficial ownership of securities held by PFCF I, and this report shall not be deemed an admission that the Reporting Person, Flint, or PFCM is the beneficial owner of these securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

F4: Shares subject to the option vest on the earlier of (i) July 28, 2027 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders.

Tectonic Therapeutic, Inc.

Report date June 09, 2025 · Filed June 11, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.48 · Expires 2035-06-08	Direct	10,200	Reported balance After 2025-06-09 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2025-06-09 · Grant · Acquired 10,200 · Balance 10,200 F1: The option shall vest in full on the earliest of (i) June 9, 2026, (ii) the date of the Issuer's 2026 Annual Meeting of stockholders, or (iii) a "Change in Control" (as defined in the Issuer's 2024 Equity Incentive Plan) of the Issuer, subject in each case, to the Reporting Person providing continuous service to the Issuer on each such date.

Filing footnotes · ownership attribution and instrument terms

F1: The option shall vest in full on the earliest of (i) June 9, 2026, (ii) the date of the Issuer's 2026 Annual Meeting of stockholders, or (iii) a "Change in Control" (as defined in the Issuer's 2024 Equity Incentive Plan) of the Issuer, subject in each case, to the Reporting Person providing continuous service to the Issuer on each such date.

X4 Pharmaceuticals, Inc

Report date June 05, 2018 · Filed June 07, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.99 · Expires 2028-06-04	Direct	10,000	Reported balance After 2018-06-05 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2018-06-05 · Grant · Acquired 10,000 · Balance 10,000 F1: The option becomes exercisable as to 1/12th of the shares underlying the award on the one-month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the Reporting Person's continued service as a director through each applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The option becomes exercisable as to 1/12th of the shares underlying the award on the one-month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the Reporting Person's continued service as a director through each applicable vesting date.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

IRONWOOD PHARMACEUTICALS INC

Report date April 01, 2019 · Filed April 03, 2019

Section 16 reporting ended · disclosed 2019-04-03. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	73,630	Reported balance After 2019-04-01 transaction · row 1 1 source row Row 1 · 2019-04-01 · Disposition to issuer · Disposed 4,056 · Balance 73,630 F1: Represents the disposition of 4,056 shares of restricted stock in connection with the separation of Cyclerion Therapeutics, Inc. ("Cyclerion") from Ironwood Pharmaceuticals, Inc. in exchange for restricted shares of Cyclerion Common Stock.
Class A Common StockSEC Table I · non-derivative	IndirectBy Polaris Venture Management Co. II, L.L.C.	1,626	Reported balance Holding disclosure · report date 2019-04-01 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 1,626 F2: The reporting person is a managing member of Polaris Venture Management Co. II, L.L.C., the beneficial owner of the securities. The reporting person disclaims beneficial ownership of the reported securities, except to the extent of his pecuniary interest therein.
Class A Common StockSEC Table I · non-derivative	IndirectBy Bartlett Partners, LLC	69,117	Reported balance Holding disclosure · report date 2019-04-01 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 69,117 F3: The reporting person is a managing member of Bartlett Partners, LLC, the beneficial owner of the securities. The reporting person disclaims beneficial ownership of the securities, except to the extent of his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the disposition of 4,056 shares of restricted stock in connection with the separation of Cyclerion Therapeutics, Inc. ("Cyclerion") from Ironwood Pharmaceuticals, Inc. in exchange for restricted shares of Cyclerion Common Stock.

F2: The reporting person is a managing member of Polaris Venture Management Co. II, L.L.C., the beneficial owner of the securities. The reporting person disclaims beneficial ownership of the reported securities, except to the extent of his pecuniary interest therein.

F3: The reporting person is a managing member of Bartlett Partners, LLC, the beneficial owner of the securities. The reporting person disclaims beneficial ownership of the securities, except to the extent of his pecuniary interest therein.

Phreesia, Inc.

Report date December 17, 2019 · Filed December 18, 2019

Jointly reported with Polaris Venture Management Co. V, L.L.C., Polaris Venture Partners Founders' Fund V, L.P., Polaris Venture Partners V, L.P., Polaris Venture Partners Entrepreneurs' Fund V, L.P., Polaris Venture Partners Special Founders' Fund V, L.P., Flint Jonathan A

Section 16 reporting ended · disclosed 2019-12-18. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy Polaris Venture Partners V, L.P.	3,101,386	Reported balance After 2019-12-17 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2019-12-17 · Sale · Disposed 344,599 · Balance 3,101,386 F1: These shares were sold in a firm commitment underwritten public offering pursuant to an underwriting agreement dated as of December 12, 2019 by and among the Issuer, the several underwriters and the selling stockholders identified therein. F2: Jonathan A. Flint ("Flint") and Terrance G. McGuire ("McGuire") are the managing members of Polaris Venture Management Co. V, L.L.C. ("PVM"), which is the sole general partner for each of Polaris Venture Partners V, L.P. ("PVP V"), Polaris Venture Partners Entrepreneurs' Fund V, L.P. ("PVPEF V"), Polaris Venture Partners Founders' Fund V, L.P. ("PVPFF V"), and Polaris Venture Partners Special Founders' Fund V, L.P. ("PVPSF V", and together with PVP V, PVPEF V, and PVPFF V, the "Polaris Funds"). Each of Flint, McGuire, and PVM may be deemed to beneficially own the shares held by the Polaris Funds, but Flint, McGuire and PVM disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein.
Common StockSEC Table I · non-derivative	IndirectBy Polaris Venture Partners Entrepreneurs' Fund V, L.P.	60,446	Reported balance After 2019-12-17 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2019-12-17 · Sale · Disposed 6,716 · Balance 60,446 F1: These shares were sold in a firm commitment underwritten public offering pursuant to an underwriting agreement dated as of December 12, 2019 by and among the Issuer, the several underwriters and the selling stockholders identified therein. F2: Jonathan A. Flint ("Flint") and Terrance G. McGuire ("McGuire") are the managing members of Polaris Venture Management Co. V, L.L.C. ("PVM"), which is the sole general partner for each of Polaris Venture Partners V, L.P. ("PVP V"), Polaris Venture Partners Entrepreneurs' Fund V, L.P. ("PVPEF V"), Polaris Venture Partners Founders' Fund V, L.P. ("PVPFF V"), and Polaris Venture Partners Special Founders' Fund V, L.P. ("PVPSF V", and together with PVP V, PVPEF V, and PVPFF V, the "Polaris Funds"). Each of Flint, McGuire, and PVM may be deemed to beneficially own the shares held by the Polaris Funds, but Flint, McGuire and PVM disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein.
Common StockSEC Table I · non-derivative	IndirectBy Polaris Venture Partners Founders' Fund V, L.P.	21,245	Reported balance After 2019-12-17 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2019-12-17 · Sale · Disposed 2,360 · Balance 21,245 F1: These shares were sold in a firm commitment underwritten public offering pursuant to an underwriting agreement dated as of December 12, 2019 by and among the Issuer, the several underwriters and the selling stockholders identified therein. F2: Jonathan A. Flint ("Flint") and Terrance G. McGuire ("McGuire") are the managing members of Polaris Venture Management Co. V, L.L.C. ("PVM"), which is the sole general partner for each of Polaris Venture Partners V, L.P. ("PVP V"), Polaris Venture Partners Entrepreneurs' Fund V, L.P. ("PVPEF V"), Polaris Venture Partners Founders' Fund V, L.P. ("PVPFF V"), and Polaris Venture Partners Special Founders' Fund V, L.P. ("PVPSF V", and together with PVP V, PVPEF V, and PVPFF V, the "Polaris Funds"). Each of Flint, McGuire, and PVM may be deemed to beneficially own the shares held by the Polaris Funds, but Flint, McGuire and PVM disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein.
Common StockSEC Table I · non-derivative	IndirectBy Polaris Venture Partners Special Founders' Fund V, L.P.	31,015	Reported balance After 2019-12-17 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 4 · 2019-12-17 · Sale · Disposed 3,446 · Balance 31,015 F1: These shares were sold in a firm commitment underwritten public offering pursuant to an underwriting agreement dated as of December 12, 2019 by and among the Issuer, the several underwriters and the selling stockholders identified therein. F2: Jonathan A. Flint ("Flint") and Terrance G. McGuire ("McGuire") are the managing members of Polaris Venture Management Co. V, L.L.C. ("PVM"), which is the sole general partner for each of Polaris Venture Partners V, L.P. ("PVP V"), Polaris Venture Partners Entrepreneurs' Fund V, L.P. ("PVPEF V"), Polaris Venture Partners Founders' Fund V, L.P. ("PVPFF V"), and Polaris Venture Partners Special Founders' Fund V, L.P. ("PVPSF V", and together with PVP V, PVPEF V, and PVPFF V, the "Polaris Funds"). Each of Flint, McGuire, and PVM may be deemed to beneficially own the shares held by the Polaris Funds, but Flint, McGuire and PVM disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein.

Filing footnotes · ownership attribution and instrument terms

F1: These shares were sold in a firm commitment underwritten public offering pursuant to an underwriting agreement dated as of December 12, 2019 by and among the Issuer, the several underwriters and the selling stockholders identified therein.

F2: Jonathan A. Flint ("Flint") and Terrance G. McGuire ("McGuire") are the managing members of Polaris Venture Management Co. V, L.L.C. ("PVM"), which is the sole general partner for each of Polaris Venture Partners V, L.P. ("PVP V"), Polaris Venture Partners Entrepreneurs' Fund V, L.P. ("PVPEF V"), Polaris Venture Partners Founders' Fund V, L.P. ("PVPFF V"), and Polaris Venture Partners Special Founders' Fund V, L.P. ("PVPSF V", and together with PVP V, PVPEF V, and PVPFF V, the "Polaris Funds"). Each of Flint, McGuire, and PVM may be deemed to beneficially own the shares held by the Polaris Funds, but Flint, McGuire and PVM disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
November 20, 2017 Filed Nov 20, 2017 22:36 UTC	X4 Pharmaceuticals, Inc ASNS · Entity 5638	ConversionCommon Stock	1,667	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-17-027007 · doc4.xml · nonDerivative · entry 7 MCGUIRE TERRANCE · CIK 0001117003 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,796 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · price: The Series A-2 Convertible Preferred Stock converted into Common Stock on a 0.35785-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date. F5 · ownership.nature: These shares are owned directly by Polaris Founders' V, whose general partner is Polaris Management. Each of Flint and the Reporting Person are the managing members of Polaris Management and may each be deemed to share voting and dispositive power over the shares held by each of the Polaris V Funds. Polaris Management may be deemed to have sole power to vote and dispose of the shares held by the Polaris V Funds. Each of Flint, the Reporting Person and Polaris Management disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
November 20, 2017 Filed Nov 20, 2017 22:36 UTC	X4 Pharmaceuticals, Inc ASNS · Entity 5638	ConversionCommon Stock	4,743	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-17-027007 · doc4.xml · nonDerivative · entry 6 MCGUIRE TERRANCE · CIK 0001117003 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,110 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · price: The Series A-2 Convertible Preferred Stock converted into Common Stock on a 0.35785-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date. F4 · ownership.nature: These shares are owned directly by Polaris Entrepreneurs' V, whose general partner is Polaris Management. Each of Flint and the Reporting Person are the managing members of Polaris Management and may each be deemed to share voting and dispositive power over the shares held by each of the Polaris V Funds. Polaris Management may be deemed to have sole power to vote and dispose of the shares held by the Polaris V Funds. Each of Flint, the Reporting Person and Polaris Management disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
November 20, 2017 Filed Nov 20, 2017 22:36 UTC	X4 Pharmaceuticals, Inc ASNS · Entity 5638	ConversionCommon Stock	243,385	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-17-027007 · doc4.xml · nonDerivative · entry 5 MCGUIRE TERRANCE · CIK 0001117003 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 262,233 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · price: The Series A-2 Convertible Preferred Stock converted into Common Stock on a 0.35785-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date. F2 · ownership.nature: These shares are owned directly by Polaris Venture Partners V, L.P. ("Polaris V"), whose general partner is Polaris Venture Management Co. V, L.L.C. ("Polaris Management"). Each of Jonathan A. Flint ("Flint") and the Reporting Person, are the managing members of Polaris Management and may each be deemed to share voting and dispositive power with respect to the shares held by each of Polaris V, Polaris Venture Partners Entrepreneurs' Fund V, L.P. ("Polaris Entrepreneurs' V"), Polaris Venture Partners Founders' Fund V, L.P. ("Polaris Founders' V") and Polaris Venture Partners Special Founders' Fund V, L.P. ("Polaris Special Founders' V", and together with Polaris V, Polaris Entrepreneurs' V and Polaris Founders' V, the "Polaris V Funds"). F3 · ownership.nature: (Continued from footnote 2) Polaris Management may be deemed to have sole power to vote and dispose of the shares held by the Polaris V Funds. Each of Flint, the Reporting Person and Polaris Management disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
November 20, 2017 Filed Nov 20, 2017 22:36 UTC	X4 Pharmaceuticals, Inc ASNS · Entity 5638	ConversionCommon Stock	188	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-17-027007 · doc4.xml · nonDerivative · entry 4 MCGUIRE TERRANCE · CIK 0001117003 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 188 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A-1 Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-1 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date. F6 · ownership.nature: These shares are owned directly by Polaris Special Founders' V, whose general partner is Polaris Management. Each of Flint and the Reporting Person are the managing members of Polaris Management and, may each be deemed to share voting and dispositive power over the shares held by each of the Polaris V Funds. Polaris Management may be deemed to have sole power to vote and dispose of the shares held by the Polaris V Funds. Each of Flint, the Reporting Person and Polaris Management disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
November 20, 2017 Filed Nov 20, 2017 22:36 UTC	X4 Pharmaceuticals, Inc ASNS · Entity 5638	ConversionCommon Stock	129	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-17-027007 · doc4.xml · nonDerivative · entry 3 MCGUIRE TERRANCE · CIK 0001117003 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 129 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A-1 Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-1 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date. F5 · ownership.nature: These shares are owned directly by Polaris Founders' V, whose general partner is Polaris Management. Each of Flint and the Reporting Person are the managing members of Polaris Management and may each be deemed to share voting and dispositive power over the shares held by each of the Polaris V Funds. Polaris Management may be deemed to have sole power to vote and dispose of the shares held by the Polaris V Funds. Each of Flint, the Reporting Person and Polaris Management disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
November 20, 2017 Filed Nov 20, 2017 22:36 UTC	X4 Pharmaceuticals, Inc ASNS · Entity 5638	ConversionCommon Stock	367	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-17-027007 · doc4.xml · nonDerivative · entry 2 MCGUIRE TERRANCE · CIK 0001117003 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 367 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A-1 Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-1 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date. F4 · ownership.nature: These shares are owned directly by Polaris Entrepreneurs' V, whose general partner is Polaris Management. Each of Flint and the Reporting Person are the managing members of Polaris Management and may each be deemed to share voting and dispositive power over the shares held by each of the Polaris V Funds. Polaris Management may be deemed to have sole power to vote and dispose of the shares held by the Polaris V Funds. Each of Flint, the Reporting Person and Polaris Management disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
November 20, 2017 Filed Nov 20, 2017 22:36 UTC	X4 Pharmaceuticals, Inc ASNS · Entity 5638	ConversionCommon Stock	18,848	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-17-027007 · doc4.xml · nonDerivative · entry 1 MCGUIRE TERRANCE · CIK 0001117003 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 18,848 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A-1 Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-1 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date. F2 · ownership.nature: These shares are owned directly by Polaris Venture Partners V, L.P. ("Polaris V"), whose general partner is Polaris Venture Management Co. V, L.L.C. ("Polaris Management"). Each of Jonathan A. Flint ("Flint") and the Reporting Person, are the managing members of Polaris Management and may each be deemed to share voting and dispositive power with respect to the shares held by each of Polaris V, Polaris Venture Partners Entrepreneurs' Fund V, L.P. ("Polaris Entrepreneurs' V"), Polaris Venture Partners Founders' Fund V, L.P. ("Polaris Founders' V") and Polaris Venture Partners Special Founders' Fund V, L.P. ("Polaris Special Founders' V", and together with Polaris V, Polaris Entrepreneurs' V and Polaris Founders' V, the "Polaris V Funds"). F3 · ownership.nature: (Continued from footnote 2) Polaris Management may be deemed to have sole power to vote and dispose of the shares held by the Polaris V Funds. Each of Flint, the Reporting Person and Polaris Management disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
November 15, 2017 Filed Dec 1, 2017 22:22 UTC	X4 Pharmaceuticals, Inc ASNS · Entity 5638	GrantStock Option (right to buy) · Derivative	7,324	$0.00 Strike: $10.00	$0.00	Disclosure SEC source: 0000899243-17-027829 · doc4.xml · derivative · entry 1 MCGUIRE TERRANCE · CIK 0001117003 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,324 Underlying: Common Stock · 7,324 shares Expires 2027-11-14 F1 · security: Consists of an automatic stock option grant that was made on November 15, 2017, the date of the effectiveness of the registration statement for the issuer's initial public offering, under the issuer's director compensation program. F2 · derivative.exercise_date: The option becomes exercisable as to 33.3333% of the shares underlying the award on the first anniversary of the date of grant, with the remainder vesting in equal monthly installments until the third anniversary of the date of grant, subject to the Reporting Person's continued service as a director through each applicable vesting date. Read SEC document
November 15, 2017 Filed Mar 9, 2018 02:20 UTC Amendment	X4 Pharmaceuticals, Inc ASNS · Entity 5638	GrantCommon Stock (right to buy) · Derivative	25,000	$0.00 Strike: $10.00	$0.00	Disclosure SEC source: 0001209191-18-018379 · doc4a.xml · derivative · entry 1 MCGUIRE TERRANCE · CIK 0001117003 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-11-14 F1 · shares: Consists of an automatic stock option grant that was made pursuant to the issuer's director compensation policy on November 15, 2017, the date of effectiveness of the registration statement for the issuer's initial public offering. Under the terms of the policy, the Reporting Person received an option to purchase 25,000 shares. Due to a clerical error, the original Form 4 filed on December 1, 2017 erroneously reported an option grant of 7,324 shares. This Amendment to Form 4 is filed solely to correct the share number. F2 · derivative.exercise_date: The option becomes exercisable as to 33.3333% of the shares underlying the award on the first anniversary of the date of grant, with the remainder vesting in equal monthly installments until the third anniversary of the date of grant, subject to the Reporting Person's continued service as a director through each applicable vesting date. Read SEC document
September 15, 2017 Filed Sep 19, 2017 20:19 UTC	IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213	GrantClass A Common Stock	153	$0.00	$0.00	Disclosure SEC source: 0001209191-17-053286 · doc4.xml · nonDerivative · entry 1 MCGUIRE TERRANCE · CIK 0001117003 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,476 F1 · kind: Issued pursuant to the Director Compensation Plan, effective as of January 2014. Read SEC document
June 15, 2017 Filed Jun 19, 2017 20:18 UTC	IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213	GrantClass A Common Stock	142	$0.00	$0.00	Disclosure SEC source: 0001209191-17-040809 · doc4.xml · nonDerivative · entry 1 MCGUIRE TERRANCE · CIK 0001117003 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,323 F1 · kind: Issued pursuant to the Director Compensation Plan, effective as of January 2014. Read SEC document
May 31, 2017 Filed Jun 2, 2017 21:01 UTC	IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213	GrantClass A Common Stock	15,625	$0.00	$0.00	Disclosure SEC source: 0001209191-17-037352 · doc4.xml · nonDerivative · entry 1 MCGUIRE TERRANCE · CIK 0001117003 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,181 F1 · kind: Issued pursuant to the Director Compensation Plan, effective as of January 2014. Read SEC document
March 20, 2017 Filed Mar 22, 2017 22:53 UTC	Pulmatrix, Inc. PULM · Entity 8249	GrantStock Option (Right to Buy) · Derivative	4,400	$0.00 Strike: $2.78	$0.00	Disclosure SEC source: 0000899243-17-008416 · doc4.xml · derivative · entry 1 MCGUIRE TERRANCE · CIK 0001117003 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,400 Underlying: Common Stock · 4,400 shares Expires 2027-03-20 F1 · derivative.exercise_date: The option vests as to 25% on March 20, 2018 and the remaining 75% vests in thirty-six (36) equal monthly installments with 2.083% vesting for each of the next thirty-six (36) months that follow March 20, 2018, subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan. Read SEC document
March 15, 2017 Filed Mar 16, 2017 21:09 UTC	IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213	GrantClass A Common Stock	142	$0.00	$0.00	Disclosure SEC source: 0001209191-17-021131 · doc4.xml · nonDerivative · entry 1 MCGUIRE TERRANCE · CIK 0001117003 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,556 F1 · kind: Issued pursuant to the Director Compensation Plan, effective as of January 2014. Read SEC document
March 02, 2017 Filed Mar 14, 2017 22:22 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	GrantOption to Purchase Common Stock · Derivative	7,500	$0.00 Strike: $30.17	$0.00	Disclosure SEC source: 0001179110-17-004598 · edgar.xml · derivative · entry 2 MCGUIRE TERRANCE · CIK 0001117003 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2027-03-02 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award vest in full on the one year anniversary of the grant date. Read SEC document
March 02, 2017 Filed Mar 14, 2017 22:22 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	GrantCommon Stock	1,250	$0.00	$0.00	Disclosure SEC source: 0001179110-17-004598 · edgar.xml · nonDerivative · entry 1 MCGUIRE TERRANCE · CIK 0001117003 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,250 Read SEC document
December 21, 2016 Filed Dec 22, 2016 21:29 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	OtherCommon Stock	2,190	$0.00	$0.00	Disclosure SEC source: 0000899243-16-036248 · doc4.xml · nonDerivative · entry 2 MCGUIRE TERRANCE · CIK 0001117003 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,814 F1 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Polaris Venture Partners IV, L.P. ("PVP IV") and Polaris Venture Partners Entrepreneurs' Fund IV, L.P. ("PVPE IV" and, together with PVP IV, the "Funds") to their respective limited partners and general partner, Polaris Venture Management Co. IV, L.L.C. ("PVM IV"). Read SEC document
December 21, 2016 Filed Dec 22, 2016 21:29 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	OtherCommon Stock	747,127	$0.00	$0.00	Disclosure SEC source: 0000899243-16-036248 · doc4.xml · nonDerivative · entry 1 MCGUIRE TERRANCE · CIK 0001117003 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F1 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Polaris Venture Partners IV, L.P. ("PVP IV") and Polaris Venture Partners Entrepreneurs' Fund IV, L.P. ("PVPE IV" and, together with PVP IV, the "Funds") to their respective limited partners and general partner, Polaris Venture Management Co. IV, L.L.C. ("PVM IV"). F2 · shares: Represents 725,005 shares distributed by PVP IV to its limited partners, 12,708 shares distributed by PVPE IV to its limited partners and 9,414 shares distributed by PVM IV to its members, including the Reporting Person. In connection with the foregoing distributions by the Funds, the Funds distributed an aggregate of 7,419 shares to PVM IV, which merely constituted a change of the form of beneficial ownership of the shares. These distributions were effected in accordance with the terms of the governing documents of each of PVP IV, PVPE IV and PVM IV. F3 · ownership.nature: The Reporting Person is a managing member of PVM IV, the general partner of each of PVP IV and PVPE IV. The Reporting Person disclaims beneficial ownership of the Funds' and PVM IV's securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest, if any, therein. Read SEC document
December 15, 2016 Filed Dec 19, 2016 22:35 UTC	IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213	GrantClass A Common Stock	161	$0.00	$0.00	Disclosure SEC source: 0001209191-16-155978 · doc4.xml · nonDerivative · entry 1 MCGUIRE TERRANCE · CIK 0001117003 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,414 F1 · kind: Issued pursuant to the Director Compensation Plan, effective as of January 2014. Read SEC document
December 08, 2016 Filed Dec 9, 2016 23:22 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	SaleCommon Stock	643	$30.96	$19,907.28	Disclosure SEC source: 0000899243-16-035262 · doc4.xml · nonDerivative · entry 4 MCGUIRE TERRANCE · CIK 0001117003 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 747,127 F6 · kind: On December 7, 2016, the PVPE IV exercised a warrant to purchase 3,384 share of the Issuer's Common Stock for $5.88 per share. PVPE IV paid the exercise price on a cashless basis, resulting in the Issuer withholding 643 shares of the Issuer's shares of common stock subject to the warrant to pay the exercise price and issuing PVPE IV the remaining 2,741 shares of the Issuer's common stock. The Issuer also paid $9.36 to PVPE IV in lieu of a fractional share. F7 · balance_after: Represents 732,289 shares, 12,843 shares, and 1,995 shares directly owned by PVP IV, PVPE IV and PVM IV, respectively. F2 · ownership.nature: The Reporting Person is a managing member of PVM IV, the general partner of each of PVP IV and PVPE IV. The Reporting Person disclaims beneficial ownership of the Funds' and PVM IV's securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest, if any, therein. Read SEC document
December 08, 2016 Filed Dec 9, 2016 23:22 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	SaleCommon Stock	34,285	$30.96	$1,061,463.60	Disclosure SEC source: 0000899243-16-035262 · doc4.xml · nonDerivative · entry 2 MCGUIRE TERRANCE · CIK 0001117003 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 744,386 F3 · kind: On December 7, 2016, the PVP IV exercised a warrant to purchase 180,518 share of the Issuer's Common Stock for $5.88 per share. PVP IV paid the exercise price on a cashless basis, resulting in the Issuer withholding 34,285 shares of the Issuer's shares of common stock subject to the warrant to pay the exercise price and issuing PVP IV the remaining 146,233 shares of the Issuer's common stock. The Issuer also paid $17.76 to PVP IV in lieu of a fractional share. F4 · balance_after: Represents 732,289 shares, 10,102 shares, and 1,995 shares directly owned by PVP IV, PVPE IV and PVM IV, respectively. F2 · ownership.nature: The Reporting Person is a managing member of PVM IV, the general partner of each of PVP IV and PVPE IV. The Reporting Person disclaims beneficial ownership of the Funds' and PVM IV's securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest, if any, therein. Read SEC document
December 07, 2016 Filed Dec 9, 2016 23:22 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	OtherWarrant (Right to Buy) · Derivative	3,384	$0.00 Strike: $5.88	$0.00	Disclosure SEC source: 0000899243-16-035262 · doc4.xml · derivative · entry 7 MCGUIRE TERRANCE · CIK 0001117003 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 3,384 shares Expires 2020-06-10 F2 · ownership.nature: The Reporting Person is a managing member of PVM IV, the general partner of each of PVP IV and PVPE IV. The Reporting Person disclaims beneficial ownership of the Funds' and PVM IV's securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest, if any, therein. Read SEC document
December 07, 2016 Filed Dec 9, 2016 23:22 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	OtherWarrant (Right to Buy) · Derivative	180,518	$0.00 Strike: $5.88	$0.00	Disclosure SEC source: 0000899243-16-035262 · doc4.xml · derivative · entry 6 MCGUIRE TERRANCE · CIK 0001117003 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 180,518 shares Expires 2020-06-10 F2 · ownership.nature: The Reporting Person is a managing member of PVM IV, the general partner of each of PVP IV and PVPE IV. The Reporting Person disclaims beneficial ownership of the Funds' and PVM IV's securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest, if any, therein. Read SEC document
December 07, 2016 Filed Dec 9, 2016 23:22 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	OtherCommon Stock	3,384	$5.88	$19,897.92	Disclosure SEC source: 0000899243-16-035262 · doc4.xml · nonDerivative · entry 3 MCGUIRE TERRANCE · CIK 0001117003 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 747,770 F5 · balance_after: Represents 732,289 shares, 13,486 shares, and 1,995 shares directly owned by PVP IV, PVPE IV and PVM IV, respectively. F2 · ownership.nature: The Reporting Person is a managing member of PVM IV, the general partner of each of PVP IV and PVPE IV. The Reporting Person disclaims beneficial ownership of the Funds' and PVM IV's securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest, if any, therein. Read SEC document
December 07, 2016 Filed Dec 9, 2016 23:22 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	OtherCommon Stock	180,518	$5.88	$1,061,445.84	Disclosure SEC source: 0000899243-16-035262 · doc4.xml · nonDerivative · entry 1 MCGUIRE TERRANCE · CIK 0001117003 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 778,671 F1 · balance_after: Represents 766,574 shares, 10,102 shares, and 1,995 shares directly owned by Polaris Venture Partners IV, L.P. ("PVP IV"), Polaris Venture Partners Entrepreneurs' Fund IV, L.P. ("PVPE IV") and Polaris Venture Management IV, L.L.C. ("PVM IV"), respectively. F2 · ownership.nature: The Reporting Person is a managing member of PVM IV, the general partner of each of PVP IV and PVPE IV. The Reporting Person disclaims beneficial ownership of the Funds' and PVM IV's securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest, if any, therein. Read SEC document
November 18, 2016 Filed Nov 21, 2016 22:45 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	OtherCommon Stock	1,624	$0.00	$0.00	Disclosure SEC source: 0000899243-16-034030 · doc4.xml · nonDerivative · entry 3 MCGUIRE TERRANCE · CIK 0001117003 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,624 F5 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by PVM IV to its members and assignees. Read SEC document
November 18, 2016 Filed Nov 21, 2016 22:45 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	OtherCommon Stock	6,980	$0.00	$0.00	Disclosure SEC source: 0000899243-16-034030 · doc4.xml · nonDerivative · entry 2 MCGUIRE TERRANCE · CIK 0001117003 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 598,153 F5 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by PVM IV to its members and assignees. F5 · shares: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by PVM IV to its members and assignees. F6 · balance_after: Represents 586,056 shares, 10,102 shares, and 1,995 shares directly owned by PVP IV, PVPE IV and PVM IV, respectively. F4 · ownership.nature: The Reporting Person is a managing member of PVM IV, the general partner of each of PVP IV and PVPE IV. The Reporting Person disclaims beneficial ownership of the Funds' and PVM IV's securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest, if any, therein. Read SEC document
November 17, 2016 Filed Nov 21, 2016 22:45 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	OtherCommon Stock	693,020	$0.00	$0.00	Disclosure SEC source: 0000899243-16-034030 · doc4.xml · nonDerivative · entry 1 MCGUIRE TERRANCE · CIK 0001117003 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 605,133 F1 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Polaris Venture Partners IV, L.P. ("PVP IV") and Polaris Venture Partners Entrepreneurs' Fund IV, L.P. ("PVPE IV" and, together with PVP IV, the "Funds") to their respective limited partners. In addition, in connection with the above mentioned distribution, each of, PVP IV distributed 6,850 shares and PVPE IV distributed 130 shares to Polaris Venture Management Co. IV, L.L.C. ("PVM IV"). The distribution of these 6,980 shares by PVP IV and PVPE IV to PVM IV is an exempt transaction and not reported in column 4 because the transaction merely reflected a change in the beneficial ownership of those shares. F2 · shares: Represents 680,269 shares distributed by PVP IV to its limited partners and 12,751 shares distributed by PVPE IV to its limited partners. F3 · balance_after: Represents 586,056 shares, 10,102 shares, and 8,975 shares directly owned by PVP IV, PVPE IV and PVM IV, respectively. F4 · ownership.nature: The Reporting Person is a managing member of PVM IV, the general partner of each of PVP IV and PVPE IV. The Reporting Person disclaims beneficial ownership of the Funds' and PVM IV's securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest, if any, therein. Read SEC document
September 15, 2016 Filed Sep 19, 2016 20:43 UTC	IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213	GrantClass A Common Stock	166	$0.00	$0.00	Disclosure SEC source: 0001209191-16-141990 · doc4.xml · nonDerivative · entry 1 MCGUIRE TERRANCE · CIK 0001117003 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,253 F1 · kind: Issued pursuant to the Director Compensation Plan, effective as of January 2014. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.